{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-103118","form_type":"8-K","ticker":"MBX","cik":"0001776111","company_name":"MBX Biosciences, Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.139698+00:00","generated_at":"2026-05-15T13:43:27.112590+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MBX Biosciences reports FY2025 net loss of $87M; Phase 3 canvuparatide on track for Q3 2026","bullets":["Net loss FY2025 $87.0M vs $61.9M in 2024; R&D expenses $79.2M, up from $57.4M.","Pro forma cash & investments $459.1M including $85.4M ATM net proceeds; runway into 2029.","Phase 3 trial of once-weekly canvuparatide for hypoparathyroidism to initiate Q3 2026 after successful End-of-Phase 2 FDA meeting.","MBX 4291 (obesity) 12-week MAD data expected Q4 2026; two additional obesity candidates to be nominated in Q2 and Q3 2026.","Appointed Laurie Stelzer to Board and Karen Basbaum as CBO in early 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-103118","json":"https://secwatch.observer/filing/0001193125-26-103118.json","markdown":"https://secwatch.observer/filing/0001193125-26-103118.md","text":"https://secwatch.observer/filing/0001193125-26-103118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526103118/0001193125-26-103118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526103118/mbx-20260312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:43:27.112590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b89c0accbe84482cb277796dc11f24570da7a4b6","claim":"MBX Biosciences, Inc. reported the full year ended December 31, 2025 results: net income $87.0 million.","evidence_excerpt":"Net loss for the full year ended December 31, 2025 was $87.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526103118/0001193125-26-103118-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Net income","value":"$87.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fef9976ad97a006e412aaf4874ffd74036bd2e3b","claim":"MBX Biosciences, Inc. reported the three months ended December 31, 2025 results: net income $22.1 million.","evidence_excerpt":"Net loss for the three months ended December 31, 2025, was $22.1 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526103118/0001193125-26-103118-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2025"},{"label":"Net income","value":"$22.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}